Comparative Pharmacology
Head-to-head clinical analysis: HARLIKU versus LAZCLUZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARLIKU versus LAZCLUZE.
HARLIKU vs LAZCLUZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
LAZCLUZE (lazertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR tyrosine kinase, including mutant forms with T790M resistance mutations and exon 19 deletions, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival.
1 mg orally once daily.
20 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (CrCl 30-50 mL/min) and >48 h in severe impairment.
The terminal elimination half-life of Lazcluze is approximately 24-30 hours, supporting once-daily dosing with steady-state achieved within 5-7 days.
Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically.
Lazcluze is primarily eliminated via biliary excretion into feces, with approximately 70-80% of the administered dose recovered as unchanged drug in feces. Renal elimination accounts for less than 10% of the dose, with less than 1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown